Costochondritis Market: Global Overview and Forecast (2022-2027) by Diagnosis, Treatment, End-User, and Region

Costochondritis Market size was valued at US$ 2.51 Bn. in 2021 and the total Costochondritis revenue is expected to grow at 4.2% through 2022 to 2027, reaching nearly US$ 3.21 Bn.

Costochondritis Market Overview:

Inflammation of the junctions where the upper ribs meet the cartilage that supports them to the breastbone is known as costochondritis (sternum). Pushing on the affected cartilage in the front of the rib cage can induce localized chest wall discomfort and soreness, which can be recreated by pressing on the concerned cartilage. It's a pretty innocuous muscular chest ache that normally goes away on its own. In most cases, the cause is untraceable. Costochondritis Market To know about the Research Methodology :- Request Free Sample Report The frequency of cardiac chest discomfort in the general population was 6.5 per 1,000 people per year, according to data from hospitals and primary care in North America. According to population-based questionnaire research, over 20% of individuals have chest discomfort over a year. When compared to a control group with no chest pain, there is a 3% increase in fatality one year after contacting a Physician about the development of chest pain, with the excess related mostly to cardiovascular disease. The epidemiology of chest discomfort in ambulatory and emergency settings differs significantly. More than half of patients arriving at the emergency department with chest pain have a cardiovascular disease e.g. myocardial infarction, angina, pulmonary embolism, or heart failure. Musculoskeletal problems, gastrointestinal disease, unstable coronary artery disease, anxiety symptoms or other mental conditions, and pulmonary disease are the most prevalent causes of chest discomfort observed in ambulatory general practice. In this report, the Costochondritis market's growth reasons, as well as the market's many segments (Diagnosis, Treatment, End-User, and Region), are discussed. Data has been given by market players, regions, and specific requirements. This market report includes a comprehensive overview of all the significant improvements that are presently prevailing in all market segments. Key data analysis is presented in the form of statistics, infographics, and presentations. The study discusses the Costochondritis market's Drivers, Restraints, Opportunities, and Challenges. The report helps to assess the market growth drivers and determines how to use these drivers as a tool. The report also helps to rectify and resolve issues related to the global Costochondritis market situation.

Costochondritis Market Dynamics:

• The primary driver of the market is the fact that cardiovascular diseases are becoming more common. The biggest cause of mortality globally is cardiovascular disease. According to the World Health Organization, cardiovascular disease is the leading cause of mortality worldwide, with over 35 million individuals experiencing a heart attack or stroke each year. According to the American Heart Association, approximately half of all individuals in the United States suffer from cardiovascular disease. It D is expected to affect more than 120 million individuals, or 40.2% of the US population, by 2030. The disease is influenced by a number of variables, including family history, ethnicity, and age. Tobacco use, hypertension, high blood cholesterol, obesity, physical inactivity, diabetes, poor diets, and alcohol consumption are all risk factors. • The major restraint of the market is that medical reimbursement for bone-related diseases is limited. At a country level, medical reimbursement is one of the most important variables influencing the acceptance and demand of certain diagnostic or therapeutic goods among patients and healthcare professionals. In developed nations e.g. the United States, many healthcare insurance companies cover bone disease drugs provided certain requirements are met. In the United States, for example, insurance covers bone ailment if the intended bones are differentiated little less than one centimeter and are not infected. • The key opportunity in the market is the prevalence of point of care testing with cardiac biomarkers. The need for point-of-care testing kits has risen dramatically in recent years, owing to a growth in the number of cardiovascular disease patients in emergency rooms who require an immediate diagnosis. Because of the benefits it provides, cardiac biomarker testing is becoming more widely used in diagnostic processes for cardiovascular disorders across the world. Reduced duration of stay, higher Key market participants are increasingly focused on establishing technologically sophisticated points of care for cardiovascular illnesses to capitalize on the prospects in this area.

Costochondritis Market Segment Analysis:

By Treatment, the anti-inflammatory drug segment dominated the market in 2020. It is expected to grow at a CAGR of 6.7% in the aforementioned forecast period. Anti-inflammatory medicines are being used more often to treat autoimmune inflammatory disorders. The market is expected to grow because of the lower adverse effects compared to traditional medications. Furthermore, there has been an increase in the use of corticosteroids to treat chronic obstructive pulmonary diseases and asthma. The worldwide anti-inflammatory therapeutics market is growing due to an increase in the incidence of autoimmune illnesses and chronic respiratory problems, the introduction of novel medications, and an increase in the rate of anti-inflammatory drug acceptance. Anti-inflammatory medicine’s adverse effects and patent expiration, on the other hand, limit the segment growth. Biosimilars for current pharmaceuticals, on the other hand, are projected to provide profitable prospects for market players in the forecast period.

Costochondritis Market Regional Insights:

Because of reasons such as the established healthcare system with a large number of known companies, significant investment, and the need for more efficacious pharmaceuticals, North America is the largest market in the Costochondritis Market. Furthermore, high per capita income increased inpatient visits to physicians, and research breakthroughs owing to increased funding are some of the reasons that are boosting the North American market forward. However, Asia Pacific is predicted to advance at the fastest CAGR of 5.6%, thanks to a large patient pool, rising disposable incomes, increased spending on healthcare, and more health awareness. Costochondritis Market The objective of the report is to present a comprehensive analysis of the Costochondritis market to the stakeholders in the industry. The past and current status of the industry with the forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that include market leaders, followers, and new entrants. PORTER, PESTEL analysis with the potential impact of micro-economic factors of the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding the Costochondritis market dynamics, structure by analyzing the market segments and projecting the Costochondritis market size. Clear representation of competitive analysis of key players by product, price, financial position, product portfolio, growth strategies, and regional presence in the Costochondritis market make the report investor’s guide.

Costochondritis Market Scope: Inquire before buying

Global Costochondritis Market
Report Coverage Details
Base Year: 2021 Forecast Period: 2022-2027
Historical Data: 2017 to 2021 Market Size in 2021: US $ 2.51 Bn.
Forecast Period 2022 to 2027 CAGR: 4.2% Market Size in 2027: US $ 3.21 Bn.
Segments Covered: by Diagnosis • Tests • Echocardiogram • Electrocardiogram • Cardiac catheterization • Chest X-ray • Cardiac MRI • CT scan
by Treatment • Medications • Nonsteroidal anti-inflammatory drugs • Narcotics • Antidepressants • Anti-seizure drugs • Therapy • Stretching exercises • Nerve stimulation • Surgery
by End-User • Hospitals and Clinics • Ambulatory surgical centers • Diagnostic centers • Research centers • Others

Costochondritis Market, by Region

• North America • Europe • Asia Pacific • Middle East and Africa • South America

Costochondritis Market Key Players

KemPharm • GlaxoSmithKline plc • Biovail Corporation • Aurobindo Pharma • Pfizer Inc. • Recro Pharma Inc. • LUPIN • Bausch Health Companies Inc • Avenue Therapeutics • Bliss GVS Pharma • Johnson & Johnson • Novartis AG • Biogen • MED Pharma Co. Ltd. • Zydus Pharmaceuticals FAQs: 1. Which is the potential market for Costochondritis in terms of the region? Ans. North America is the largest market in the Costochondritis Market. 2. What are the opportunities for new market entrants? Ans. The key opportunity in the market is the prevalence of point of care testing with cardiac biomarkers. 3. What is expected to drive the growth of the Costochondritis market in the forecast period? Ans. The primary driver of the market is the fact that cardiovascular diseases are becoming more common. 4. What is the projected market size & growth rate of the Costochondritis Market? Ans. Costochondritis Market size was valued at US$ 2.51 Bn. in 2021 and the total Costochondritis revenue is expected to grow at 4.2% through 2022 to 2027, reaching nearly US$ 3.21 Bn. 5. What segments are covered in the Costochondritis Market report? Ans. The segments covered are Diagnosis, Treatment, End-User, and Region.
1. Global Costochondritis Market: Research Methodology 2. Global Costochondritis Market: Executive Summary 2.1 Market Overview and Definitions 2.1.1. Introduction to Global Costochondritis Market 2.2. Summary 2.1.1. Key Findings 2.1.2. Recommendations for Investors 2.1.3. Recommendations for Market Leaders 2.1.4. Recommendations for New Market Entry 3. Global Costochondritis Market: Competitive Analysis 3.1 MMR Competition Matrix 3.1.1. Market Structure by region 3.1.2. Competitive Benchmarking of Key Players 3.2 Consolidation in the Market 3.2.1 M&A by region 3.3 Key Developments by Companies 3.4 Market Drivers 3.5 Market Restraints 3.6 Market Opportunities 3.7 Market Challenges 3.8 Market Dynamics 3.9 PORTERS Five Forces Analysis 3.10 PESTLE 3.11 Regulatory Landscape by region • North America • Europe • Asia Pacific • The Middle East and Africa • Latin America 3.12 COVID-19 Impact 4. Global Costochondritis Market Segmentation 4.1 Global Costochondritis Market, by Diagnosis (2022-2027) • Tests • Echocardiogram • Electrocardiogram • Cardiac catheterization • Chest X-ray • Cardiac MRI • CT scan 4.2 Global Costochondritis Market, by Treatment (2022-2027) • Medications • Nonsteroidal anti-inflammatory drugs • Narcotics • Antidepressants • Anti-seizure drugs • Therapy • Stretching exercises • Nerve stimulation • Surgery 4.3 Global Costochondritis Market, by End-User (2022-2027) • Hospitals and Clinics • Ambulatory surgical centers • Diagnostic centers • Research centers • Others 5. North America Costochondritis Market(2022-2027) 5.1 Global Costochondritis Market, by Diagnosis (2022-2027) • Tests • Echocardiogram • Electrocardiogram • Cardiac catheterization • Chest X-ray • Cardiac MRI • CT scan 5.2 Global Costochondritis Market, by Treatment (2022-2027) • Medications • Nonsteroidal anti-inflammatory drugs • Narcotics • Antidepressants • Anti-seizure drugs • Therapy • Stretching exercises • Nerve stimulation • Surgery 5.3 Global Costochondritis Market, by End-User (2022-2027) • Hospitals and Clinics • Ambulatory surgical centers • Diagnostic centers • Research centers • Others 5.4 North America Costochondritis Market, by Country (2022-2027) • United States • Canada • Mexico 6. Asia Pacific Costochondritis Market (2022-2027) 6.1. Asia Pacific Costochondritis Market, by Diagnosis (2022-2027) 6.2. Asia Pacific Costochondritis Market, by Treatment (2022-2027) 6.2. Asia Pacific Costochondritis Market, by End-User (2022-2027) 6.2. Asia Pacific Costochondritis Market, by Country (2022-2027) • China • India • Japan • South Korea • Australia • ASEAN • Rest Of APAC 7. Middle East and Africa Costochondritis Market (2022-2027) 7.1 Middle East and Africa Costochondritis Market, by Diagnosis (2022-2027) 7.2. Middle East and Africa Costochondritis Market, by Treatment (2022-2027) 7.2. Middle East and Africa Costochondritis Market, by End-User (2022-2027) 7.4. Middle East and Africa Costochondritis Market, by Country (2022-2027) • South Africa • GCC • Egypt • Nigeria • Rest Of ME&A 8. Latin America Costochondritis Market (2022-2027) 8.1. Latin America Costochondritis Market, by Diagnosis (2022-2027) 8.2. Latin America Costochondritis Market, by Treatment (2022-2027) 8.2. Latin America Costochondritis Market, by End-User (2022-2027) 8.4 Latin America Costochondritis Market, by Country (2022-2027) • Brazil • Argentina • Rest Of Latin America 9. European Costochondritis Market (2022-2027) 9.1. European Costochondritis Market, by Diagnosis (2022-2027) 9.2. European Costochondritis Market, by Treatment (2022-2027) 9.3. European Costochondritis Market, by End-User (2022-2027) 9.4. European Costochondritis Market, by Country (2022-2027) • UK • France • Germany • Italy • Spain • Sweden • Austria • Rest Of Europe 10. Company Profile: Key players 10.1 KemPharm 10.1.1. Company Overview 10.1.2. Financial Overview 10.1.3. Global Presence 10.1.4. Capacity Portfolio 10.1.5. Business Strategy 10.1.6. Recent Developments 10.2 GlaxoSmithKline plc 10.3 Biovail Corporation 10.4 Aurobindo Pharma 10.5 Pfizer Inc. 10.6 Recro Pharma Inc. 10.7 LUPIN 10.8 Bausch Health Companies Inc 10.9 Avenue Therapeutics 10.10 Bliss GVS Pharma 10.11 Johnson & Johnson 10.12 Novartis AG 10.13 Biogen 10.14 MED Pharma Co. Ltd. 10.15 Zydus Pharmaceuticals

About This Report

Report ID 66359
Category Healthcare
Published Date July 2020
Updated Date March 2022
Contact Us